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Abstract 
 Chronic	  wounds	  can	  often	  become	  infected	  due	  to	  bacterial	  resistance	  towards	  antibiotics	  and	  a	  new	  potential	  solution	  to	  this	  resistance	  is	  to	  use	  antimicrobial	  peptides	  (AMPs)	  to	  heal	  wounds.	  	  The	  goal	  of	  this	  project	  was	  to	  determine	  the	  wound	  healing	  ability	  of	  using	  antimicrobial	  peptides	  (AMPs)	  and	  modified	  collagen-­‐binding	  AMPs	  on	  the	  ability	  of	  cells	  to	  migrate	  over	  in	  a	  bare	  area	  on	  a	  dish,	  simulating	  migration	  at	  the	  wound	  site,	  at	  varying	  AMP	  concentrations	  over	  time	  using	  scratch	  assays.	  	  In	  these	  assays,	  3	  peptides	  were	  studied	  for	  their	  ability	  to	  stimulate	  migration	  in	  human	  fibroblasts	  (CT	  1005):	  human-­‐derived	  AMP	  LL37,	  a	  modified	  synthetic	  LL37	  with	  a	  collagen-­‐binding	  domain	  (cCBD-­‐LL37),	  and	  recombinant	  cCBD-­‐LL37	  produced	  and	  harvested	  from	  H1299	  human	  lung	  carcinoma	  cells.	  	  The	  results	  showed	  that	  any	  concentration	  of	  AMP	  had	  a	  wound	  closure	  rate	  than	  the	  no	  AMP	  control,	  the	  cCBD-­‐LL37	  healed	  at	  a	  slower	  rate	  than	  LL37	  and	  the	  no	  AMP	  control,	  and	  conditioned	  media	  healed	  at	  a	  faster	  rate	  than	  a	  control	  with	  no	  conditioned	  media.	  	  The	  concentrations	  of	  AMPs	  studied	  will	  be	  valuable	  in	  the	  development	  of	  an	  AMP-­‐tethered	  collagen-­‐based	  scaffolding	  material	  to	  help	  with	  the	  healing	  of	  chronic	  wounds.	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Introduction 	  
 In the United States alone, $25 billion is spent annually on the treatment of chronic 
wounds, negatively impacting 6.5 million patients (Sen et al., 2009).  Individuals with diabetes 
and obesity often develop chronic wounds due to their weakened immune systems and the 
prevalence of these diseases is rising.  When a skin wound fails to heal within a period of 
approximately three months it is considered a chronic wound.  The inability of wounds to heal 
can also cause a lot of pain and lower quality of life for the patients affected. Patients who 
develop chronic wounds suffer from persistent inflammation and are often infected with 
microbes such as bacteria and fungi (Duplantier & van Hoek, 2013).  If a wound becomes 
infected, the body’s immune system becomes hindered and can take a much longer time period 
to heal the wound.  Further, the rise of antibiotic resistance, considered to be a “catastrophic 
threat to human health” by the Centers for Disease Control and Prevention (CDC), is severely 
complicating treatment of chronic wounds (CDC, 2014).  Over 2 million antibiotic resistant 
infections occur in the United States each year, resulting in 25,000 deaths (Discharges of 
Inpatients from Nonfederal Hospitals, 2010).  Current treatments for chronic wounds lack the 
adequate broad-spectrum antimicrobial activity needed for such diverse microbial environments 
while combating antibiotic resistance and promoting wound healing. 
 For chronic wounds, extracellular matrix (ECM)-based artificial and natural scaffolding 
materials, the most common of which are collagen-based, are used to cover the area and keep it 
moist in order to aid healing.  Once infected, the gold standard of treatment is antibiotic use, but 
as antibiotic use increases so does the resistance of bacteria.  Widespread overuse of antibiotics 
in hospitals and other care facilities have made these particularly dangerous places for 
developing infections.  Specialized sterilization procedures have been developed by the CDC in 
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order to help prevent the number of wound infections, but new therapies to combat the resistance 
already occurring are needed ("Guideline for Disinfection and Sterilization in Healthcare 
Facilities," 2009).  
 Antimicrobial peptides (AMPs) have recently been considered as viable alternative 
broad-spectrum antimicrobials that may help to heal wounds (Durr, Sudheendra, & 
Ramamoorthy, 2006).  AMPs are part of many organisms’ innate immunities, have broad-
spectrum antimicrobial activity even against resistant organisms. Some AMPs, such as the 
human-derived LL37, have been shown to promote wound healing (Durr et al., 2006).  
Unfortunately, few AMP therapies are on the market due to problems with toxicity to cells, 
stability, and high manufacturing costs (Kim, Jang, Kim, & Cho, 2013).  To overcome these 
limitations, our approach is to tether AMPs to collagen in order to target their activity in a local 
wound healing scaffold to prevent infection and promote healing.  
Main considerations for novel, AMP-based chronic wound healing treatments are 
biocompatibility and ability to promote healing.  The long-term goal of this project is to use 
recombinant cells to create collagen-based ECM scaffolding biomaterials functionalized with 
cCBD-LL37 and/or fCBD-LL37 that will help promote healing and prevent wound infection in 
chronic wounds.  Preliminary activity, toxicity and collagen-binding studies of this AMP have 
been done with synthetic cCBD-LL37, synthetic LL37, and both recombinant AMPs, cCBD-
LL37 and fCBD-LL37.  In this project, these AMPs were tested in solution for the ability to 
promote healing of CT 1005 fibroblasts in vitro over time at concentrations of 0.05-µM, 3-µM, 
and 12-µM using scratch assays.  Our hypothesis is that the addition of the cCBD moiety in the 
synthetic AMPs and both cCBD and fCBD moieties in recombinant AMPs will not be 
significantly different than unmodified LL37 at any of the concentrations, and that the highest 
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migration of the fibroblasts will be observed at the middle concentration (3-µM).  The results of 
this project could be used to help develop a new antimicrobial treatment for healing and 
preventing infection in chronic wounds. 
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Background 
Chronic Skin Wounds 
 
Chronic wounds are those that have failed to proceed through the reparative process of 
wound healing in order to return anatomic and functional integrity to the injured site within a 
time period of 3 months (Regan & Barbul).  There are 4 phases to the wound healing process; the 
hemostasis phase, inflammatory phase, proliferative phase, and maturation phase. Each phase 
has a specific function in the wound healing process as described in Figure 1.   
 
Figure 1: The four phases in the wound healing process are the hemostasis, inflammatory, 
proliferative, and maturation phases.  A normal wound proceeds through each step to heal while 
a chronic wound remains in the inflammatory phase, for an extended period of time ("Essentials 
of Wound Healing," 2015). 
 
A chronic wound is continuously in the inflammatory phase; thus, the pain for the patient 
and lowered quality of life during treatment lasts considerably longer.  Conditions including poor 
blood supply or low oxygen, infection, weakened immune systems, and tissue swelling may also 
lead to the development of a chronic wound ("Chronic Wound Care," 2015).  Individuals with 
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other health conditions such as diabetes and obesity suffer a higher risk of developing chronic 
wounds in this way, also causing complicated treatments ("Chronic Wound Care," 2015).   
 
Microbial Diversity of the Chronic Wound Environment 	  
The microbial diversity of chronic wounds (Figure 2) makes development of suitable 
multi-functional and broad-spectrum antimicrobial therapy challenging (Lipsky & Christopher, 
2009).  
 
Figure 2: The vast diversity of different bacterial species found in venous ulcers and chronic 
wounds.  Eight healing and 10 non-healing venous ulcers were tested and 19 chronic wounds 
were tested for different types of microbial species (Lipsky & Christopher, 2009). 
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The existence of complex bacterial communities residing on surfaces, called biofilms, have 
increased antibiotic resistance, induction of inflammation and pathogenesis due to secreted 
extrapolymeric substances ( 
Figure 3) and can delay healing even further (Duplantier 2013).  Biofilm-forming 
microbes persist in adhesive polymeric matrices that can severely complicate treatments. 
 
Figure 3: Bacterial biofilm formation in a skin wound environment. A cascade of responses by 
the host’s immune system is triggered in an attempt to heal the wound.  Antibiotics are also 
unable to heal the wound because they are unable to penetrate the biofilm and the secreted extra 
polymeric substances (EPS) (Duplantier & van Hoek, 2013). 
 
Hospitals are a particularly dangerous breeding ground for the development of antibiotic 
resistant bacteria.  Infections also often contain multiple microbial species of bacteria that live 
cooperatively in highly organized biofilms which means that antibiotic therapy that targets 
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specific bacteria is ineffective in treating these wounds and an individual’s immune response is 
also ineffective (Duplantier & van Hoek, 2013).  
The occurrence of resistant microbes in chronic wound infections is commonly 
developed in hospitals and care facilities due to their increased use of antibiotics.  Detailed 
sterilization procedures from the CDC are provided in order to help prevent wound infection.  
These procedures depend on whether the procedure is critical, semi-critical, or post-operative 
care.  The most common procedures require care facilities to meticulously clean patient-care 
items with water and detergent, or with water and enzymatic cleaners before high-level 
disinfection or sterilization procedures with ultrasonic cleaners, washer-disinfectors, or washer-
sterilizers are used ("Guideline for Disinfection and Sterilization in Healthcare Facilities," 2009).  
Although these procedures reduce the number of antibiotic resistant bacteria, there is a strong 
need to develop new antibiotics to replace current treatments. 
Current Forms of Treatment 
 
 One of the most important factors when deciding how to treat a skin wound is the depth 
of the wound.  There are two general ways to classify wounds; partial-thickness or full-thickness.  
An injury that extends through a portion of the dermis is considered a partial-thickness wound 
while wounds that extend through the entire dermis and parts of the subcutaneous layer are 
considered full-thickness wounds as shown in Figure 4.   
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Figure 4: Depiction of the layers of the skin and the distinction between where a partial 
thickness or full thickness skin wound would be classified.    
 
Many partial-thickness wounds can be treated with topical medications and dressings but most 
full-thickness wounds require localized regenerative therapies in order to heal the wound, 
including debridement and skin grafting (Hyakusoku, Orgill, Teot, Pribaz, & Ogawa, 2010).  It is 
important to treat the wound quickly because when it is left untreated, damaged tissue begins to 
break down and becomes susceptible to bacterial infection (James, Booth, Gilbert, Jones, & 
Shevchenko, 2008).  The main drawback of available wound dressings for chronic wound 
treatment is the absence of broad-spectrum antimicrobial activity to combat over 200 
species of bacteria that can reside in a single chronic wound (Dowd et al., 2008).   
 
Topical Antimicrobial Therapies 
 
Today, clinicians consider using topical antimicrobials for individuals who have partial-
thickness chronic wounds (Lipsky & Christopher, 2009).   Topical antimicrobials have been 
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traditionally made as ointments and creams with antibiotics or antiseptics. Several advantages 
and disadvantages to using topical antimicrobials are outlined in Figure 5 in Appendix A (Lipsky 
& Christopher, 2009).  Overall, ointments are more occlusive, often contain petrolatum, and are 
best for dry lesions while creams are less occlusive, wash off with water, are cleaner, and are 
best for moist lesions.  Newer technologies have incorporated antimicrobials into dressings to 
allow controlled release at the wound surface over time.  The major problem with these topical 
therapies is that there are no specific tests outlined by any agency in order to standardize and 
evaluate their efficacy (Lipsky & Christopher, 2009).  Also, those treatments that are released 
have sub-optimal concentrations that promote resistance in bacteria.  Figure 6 in Appendix A 
shows current topical antimicrobial wound treatments along with their advantages and 
disadvantages (Lipsky & Christopher, 2009). These treatments are not used for full-thickness 
wounds. 
 
Debridement 
 
One of the main forms of treatment for full-thickness chronic wound infections is 
debriding the wound to remove anything from the wound that can delay healing and lead to 
infection. This includes dead tissue, infected tissue, and other debris ("Chronic Wound Care," 
2015).  Common methods of debridement include surgical removal of the affected tissue, 
hydration or absorption to change moisture of the wound, and chemical breakdown of any dead 
tissue around the wound (Shai & Maibach, 2005).  This treatment is incredibly painful and 
expensive for the patient and hospitals to undertake. 
Skin grafting  
 
 Skin grafting is another form of treatment that is used when significant skin loss has 
occurred in order to support functional regeneration of the dermis especially near joints (Shai & 
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Maibach, 2005).  Skin grafts are used for wound coverage or wound closure for full-thickness 
wounds.  Most skin grafts are called autografts where healthy skin is taken from the patient’s 
own body and transplanted to the wound site in order to remove the obstacle of finding a donor 
and limit immunological rejection; however, this is not always an option for the immuno-
compromised patient.  An example is in burn victims where a large portion of their skin is 
charred, leaving limited healthy skin to harvest (James et al., 2008). Commercial scaffolding 
materials are usually made of synthetic polymers such as polyactic acid (PLA), polyglycolide 
(PGA), and copolymers or naturally-derived structural proteins, such extracellular matrix (ECM) 
(Dhandayuthapani, Yoshida, Maekawa, & Kumar, 2011).  The ECM is an attractive target for 
localizing exogenous peptide signaling molecules because it stores various skin growth factors 
that the AMP could use to help heal a wound.  A high percentage of ECM-based dressings are 
collagen-based, the most abundant structural protein in the body (Brett, 2008).  Many leading 
companies use collagen-based wound dressings such as Integra, Organogenesis, and Johnson and 
Johnson, Smith and Nephew, and LifeCell.   
 
Development of a New Antimicrobial Therapy 
 
There is a strong need to develop new antibiotics and clinicians and industry both have 
defined the ideal antimicrobial agent, outlined in Figure 7 in Appendix A.  This agent would 
target the specific antimicrobial spectrum depending on the type of infected wound.  The ideal 
treatment would be produced at a low cost, and reduce both likelihood of inducing bacterial 
resistance, and toxicity to host tissue.  The new agent would have persistent or residual skin 
activity to allow for infrequent dosing, stability in the presence of the physiologically relevant 
wound environment, and some local skin penetration but no systemic absorption.  With these 
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considerations in mind, surface-tethered antimicrobial peptides (AMPs) are among the most 
promising technologies as alternative antimicrobials. 
 
Antimicrobial Peptides (AMPs) and Human Cathelicidin LL37 
 
AMPs naturally derived, short, cationic peptides found in the innate immunity of many 
species. They are broadly active against many different types of bacteria relevant to the chronic 
wound environment and their unique mechanisms do not allow significant resistance to develop. 
They are among the most attractive alternatives to antibiotics because they evoke immune 
response to react against infection (Gabriel, Nazmi, Veerman, Nieuw Amerongen, & Zentner, 
2006). While many antibiotics utilize chemical mechanisms by specifically targeting cell surface 
biomarkers, AMPs physically penetrate the bacteria cell membranes, causing pores and eventual 
cell lysis. This physical versus chemical mechanistic difference makes AMPs more effective 
while making it more difficult for bacteria to develop resistance (Bagheri, Beyermann, & Dathe, 
2008). Cathelicidins are a family of AMPs with a conserved N-terminal cathelicidin domain, and 
are part of the mammalian innate immune defense against invasive bacterial infection.  The only 
human-derived cathelicidin is LL37, named for its 37 amino acid active domain beginning with 
two leucine residues, which is not only broadly antimicrobial but also has been shown to 
promote wound healing (Durr et al., 2006). The problem with clinical use of AMPs such as 
LL37; however, is that they are expensive to produce and may be cytotoxic in high 
concentrations.  
 The human cathelicidin peptide LL37, encoded by precursor hCAP-18 has shown 
potential in helping to treat infected chronic wounds because of its expression by epidermal 
keratinocytes and pro-healing functionality (Bourke et al., 2014).  The full structure of LL37 
contains an N-terminus signal sequence, a conserved cathelin-like domain, and an active C-
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terminus. LL37 is expressed in the neutrophils and keratinocytes of inflamed skin has shown 
promotion of wound healing at concentrations of 0.2 to 1 µM and a variety of other functions, 
summarized in Figure 8.  Concentrations above 13 µM are toxic to cells and concentrations 
below 0.2 µM demonstrate little to no effect in helping to heal the wound (Duplantier & van 
Hoek, 2013).  
 
 
Figure 8: Different concentrations for the various activities of LL37 (Duplantier & van Hoek, 
2013). 
 
This toxicity has limited LL37 to topical applications, but there is still considerable 
interest in utilizing AMPs for systemic applications, where they will be most effective.  
Lowering LL37 toxicity could allow to the therapeutic development of LL37 to treat chronic 
infected wounds (Duplantier & van Hoek, 2013).  One of the most promising solutions to using 
AMPs is to covalently or non-covalently attach them to surfaces by developing a coating to 
reduce the possibility of bacterial infection (Onaizi & Leong, 2010).  Covalent coatings would be 
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promising for preventing biofilm formation on medical implant surfaces (Ivanov, Morrison, 
Cobb, Fahey, & Camesano, 2012).  In the case of metallic surfaces, LL37 has been covalently 
tethered and has retained its activity, but this tethering may alter its ability to promote healing.  
LL37 tethering has been limited to metallic surfaces; its tethering to soft substrates such as 
collagen has not been studied in detail (Gabriel et al., 2006).   
There have been studies done regarding the wound healing ability of LL37.  One example 
was an in vitro wound-healing assay.  This assay showed that LL37 promoted keratinocyte 
(HaCaT) migration on fibronectin at concentrations up to 500 ng/ml which is important because 
proliferation and migration of human keratinocytes are important characteristics of effective 
wound healing (Carretero et al., 2008).   The cathelicidin induced an increase in the tyrosine 
phosphorylation of focal adhesion kinase, which relates to the level of human keratinocyte 
motility (Carretero et al., 2008).  Another study conducted in vivo was done in diabetic mice to 
determine the wound-healing enhancement of LL37 using retrovirus-transduced HaCaT cells and 
HaCaT cells untreated.   They found that in most of the LL37-treated wounds at days 3 to 6 post-
wounding and improved percentage of re-epithelialization.  At day 6, in most cases, the edges of 
the wounded cells, or “epithelial tongues,” had converged to completely cover the wound when 
LL37 was present and the control wounds with no LL37 still showed a gap (Carretero et al., 
2008). 
 
Modified Collagen-Binding LL37 Design  
 
 Previously recombinant forms of human cathelicidin LL37 fused to collagen-binding 
domains (CBDs) were designed.  Two CBDs, cCBD (TKKTLRT) from collagenase and fCBD 
(CQDSETGTFY) from fibronectin, were chosen, and chimeric CBD-LL37 (Figure 9), was 
expressed in human lung carcinoma cells (H1299). The long term goal of producing CBD-LL37 
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is its incorporation into a cell-derived matrix scaffold made of collagen (Prifti, 2012).  The CBD 
was added to the C-terminus of LL37, the end associated with higher hemolytic activity, in order 
to tether the peptide to the matrix (Prifti, 2012).  In order to allow flexible anchorage of the 
AMP, to aid in purification, and to allow commercial antibody recognition, a FLAG-tag 
octapeptide was used as a spacer molecule between the active domain and the CBD (Prifti, 
2012).    
 
Figure 9: Full structure of cCBD-LL37 and fCBD-LL37 precursors taken from (Prifti, 2012). 
The AMP includes three FLAG domains and the cathelin-like signal and pro-sequences, all of 
which are cleaved after cellular secretion, leaving the LL37 active domain (red), one FLAG 
sequence as a spacer and identifiable sequence (yellow) and the collagen binding domain 
(orange). 
 
Previously we have seen expected cleavage of the active domain after secretion and high 
antimicrobial activity of these recombinant peptides using Western blotting and antimicrobial 
assays.  Also, we have seen antimicrobial stability up to 3 weeks, freeze-thaw cycles, and 
lyophilization, and preliminary biocompatibility, all in solution and not tethered.  With this 
information, our goal was to study the wound healing activity of these new AMPs in solution 
based on results from a scratch assay.    
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Scratch Assay 
 
Wound healing properties can be assessed using an in vitro scratch test assay by 
measuring cell migration into a breached area on a tissue-culture plate.  Making a single scratch 
through a cell monolayer simulates this breach.  The cells will move toward the opening in order 
to close the scratch.  Cells migrate to re-establish cell-cell contacts.  In order to analyze the 
migration, images are taken of the scratched area at different time intervals until the wound is 
closed as shown in Figure 10.   
 
 
Figure 10: Example of scratch assay images of CT1005 fibroblasts at time points of 0 hours, 10 
hours, and 22 hours, showing gap closure and healing. 
 
An analysis was performed on the images taken by measuring the distance across the 
scratch.  To find gap width, lines were drawn across the scratch at a 90-degree angle and 
analyzed using image analysis software.  This distance becomes smaller over time if migration is 
occurring (Liang, Park, & Guan, 2007).  By conducting scratch assays with CT 1005 fibroblasts 
exposed to synthetic LL37, synthetic cCBD-LL37 and both recombinant cCBD-LL37 and fCBD-
LL37, we were able to study the ability of modified CBD-LL37 to promote wound healing 
versus unmodified LL37. 
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Materials and Methods 
 
Materials 	  
 The following lists materials used for the scratch assay and basic cell culture equipment 
that was used as well as the manufacturers where each was purchased.   
 Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F-12 (Hyclone Media) 
Fetal Bovine Serum (FBS) (Corning CellGro) 
 Dulbecco’s Phosphate-Buffered Saline (DPBS) (Corning CellGro) 
Glutamine (TCI) 
 Trypsin-EDTA (0.25%) (Corning CellGro) 
 10-cm dish (VWR) 
 6-well plate (Genesee Scientific) 
 CT 1005 Fibroblast Cells (Kindly donated by Dr. Tanja Dominko, WPI) 
 Synthetic peptides (cCBD-LL37 (New England Peptide, Gardner MA) and LL37   
 (Anaspec Inc., Fremont, CA) 
 Hemocytometer (VWR) 
 Zeiss Microscope (Kindly allowed permission to use by Sakthikumar Ambady) 
 Recombinant derived cCBD-LL37, fCBD-LL37, and wild-type (WT) conditioned media 
 (Provided by Dr. Denis Kole) 	  
Cell Culture Methods 
 
 When the cultured cells reached 70% confluence they were passaged.  This was done by, 
first, aspirating the medium in the flask.  Next, 5-mL of Dulbecco’s Phosphate Buffered Saline 
(DPBS) was added and aspirated to remove dead cells and other debris.  Trypsin was then added 
and the flask was rocked gently.  Five mL of 1:1 Dulbecco’s modified eagle medium/Ham’s F-
12 medium supplemented with 2.50-mM L-glutamine and 10% v/v fetal bovine serum (FBS) 
was added and mixed by pipetting up and down.  The cells were then transferred to a 15-mL 
conical tube and centrifuged (Sorvall ST 8 Centrifuge, ThermoFisher, Waltham, MA) at 100 x g 
for 5 minutes.  The supernatant medium was then aspirated and the cell pellet was re-suspended 
in 2-mL of media.  The cells were pipetted up and down and a cell count was performed with a 
hemocytometer utilizing 10-uL of the cell solution.  Once 2 cell counts were collected they were 
averaged and the number of cells per milliliter was calculated using chamber and cell solution 
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volumes.  To determine the total number of cells remaining in the 15-mL conical, the cell 
volume used for the cell count was subtracted from the final value.  The proper volume of cell 
suspension to be plated was determined by selecting the number of cells to be plated and then 
multiplying by the amount of media used to re-suspend the pellet and dividing by the number of 
cells in the 15-mL conical that was previously calculated.  The cell suspension was then re-
suspended and media was brought up to the proper final volume based on the dish on which the 
cells were plated. The cells were then placed in the incubator under humid conditions and 5.2% 
CO2 at 37°C.  Cells were checked for confluency and morphology every 24 hours. Media was 
aspirated, DPBS-rinsed, and replenished with 10-mL fresh media every 72 hours until ready to 
use in an experiment or to passage again at 70% confluence.  
 
Preparing a Confluent Monolayer 
 
Prior to starting the scratch assay, a confluent monolayer of cells was seeded onto a 6-
well plate from cells growing on a 10-cm dish. A confluent monolayer is important for a scratch 
assay test to ensure that the cells grow in the scratched area only and do not grow on other areas 
of the plate.  This is also representative of how cells would behave in vivo.  Cells were passaged 
from the dish and plated on a 6-well plate with 135,000 cells per well.  The growth area on a 6-
well plate is 10-cm2, meaning that a concentration of 13,500 cells per cm2 could be used to plate 
cells on any well plate. The cells were then allowed to attach and grow for approximately 48 
hours in order to develop a confluent monolayer.  Each scratch assay had n > 4 replicates. 
 
Baseline, (-)AMP Control  	  
Once the cells had created a confluent monolayer, a sterile 200-µL pipet tip was used to 
scratch the cells layer.  Carefully holding the pipet tip straight up and down, each well of cells 
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was scratched once close to the center of the well.  After the cells were scratched, their location 
was marked on the bottom of the plate and rinsed with DPBS to get rid of any dislodged or dead 
cells that would inhibit clear imaging.  Finally, 2-mL fresh medium was added to each well and 
the cells were allowed to incubate.  At chosen times of 0 hours, 4 hours, 10 hours, 15 hours, and 
22 hours post-scratching, photos of each scratch were taken using a 5x objective lens on a Zeiss 
phase contrast microscope.  Images were analyzed using ImageJ Analysis software, 
(http://imagej.nih.gov/ij/), using procedures described below in the data analysis section.  
 
Sample, (+)AMP, Synthetic LL37 and cCBD-LL37 AMP  
 
LL37 (Anaspec, Inc.) and cCBDLL37 (New England Peptide) AMPs were added into 
sample wells to determine (1) if adding AMP changed the closure time of the scratches 
compared to a (-) AMP control and (2) to determine if adding a cCBD moiety onto LL37 
changed its ability to promote healing. This was done by adding AMPs directly from a 0.67-mM 
stock solution made in pH 7.4 PBS supplemented with 5-mM EDTA and 3-mg/mL BSA into the 
wells for final concentrations of 0.05-µM, 3-µM, and 12-µM. AMPs were added directly after the 
DPBS rinse post-scratching and the final volume was brought up to 2-mL. All other methods 
were followed exactly and compared with the baseline control. Images were analyzed using 
ImageJ Analysis software. 
 
Sample, (+)AMP, Recombinant  cCBD-LL37 & fCBD-LL37 
 
Serum-free conditioned medium (CM) from transfected H1299 (with both types of CBD-
LL37, cCBD and fCBD) and untransfected H1299 (wild-type, WT) was collected after 90 hours 
in culture followed by overnight incubation in serum-free medium.  CM was directly added onto 
the confluent monolayer of CT 1005 fibroblasts: 1-mL of CM from cCBD-LL37, fCBD-LL37, or 
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WT samples were added into 1-mL of medium into the well of a 6-well plate. The scratch assay 
proceeded as normal, with at n > 4 replicates. Images were analyzed using ImageJ Analysis 
software.  
 
Imaging 	  
 Images were taken of the wound gaps as they healed over time with a Zeiss Microscope.  
The 5x objective lens was used on the microscope in order for the entire scratch to fit into one 
image. The images taken using the microscope at 0 hours, 4 hours, 10 hours, 15 hours and 22 
hours showed that the scratches were closing because the scratch width decreased as time passed 
in the pictures taken.   
 
Data Analysis  
 
ImageJ software, (http://imagej.nih.gov/ij/), was used to analyze all images.  For data 
analysis of the scratch width over time, each image was brought into ImageJ and the scale was 
set under the analyze tab.  For each image the distance in pixels (picture height), the known 
distance, and unit of length were all set.  The global setting was checked when the images had all 
the same dimensions.  In order to set the “known distance” for the scale of the images the 
following equation was used:  
𝐾𝑛𝑜𝑤𝑛  𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑖𝑛  𝑚𝑖𝑐𝑟𝑜𝑚𝑒𝑡𝑒𝑟𝑠 =    𝑖𝑚𝑎𝑔𝑒  ℎ𝑒𝑖𝑔ℎ𝑡  ×  10,000𝑚𝑖𝑐𝑟𝑜𝑚𝑒𝑡𝑒𝑟𝑠𝑐𝑒𝑛𝑡𝑖𝑚𝑒𝑡𝑒𝑟𝑅2.54   𝑐𝑒𝑛𝑡𝑖𝑚𝑒𝑡𝑒𝑟𝑠𝑚𝑒𝑡𝑒𝑟   ×  𝑀  
Where R was the picture pixels per inch that was found using image preview and M was the 
microscope eyepiece zoom (10x) multiplied by the objective lens (5x).  Scale bars were drawn 
on each image taken of the scratch width tests over time. 
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Scratch Width Scratch Assay Results  
 
Once the scale was set, 10, 90-degree, arbitrary lines were drawn across the scratch and 
were measured to determine the scratch width in µM as shown in Figure 11.  A table 
summarizing all scratch width results can be found in Appendix B. 
 
Figure 11: Representative image of the scratch width data analysis.  This image is with 3 µM 
cCBD -LL37 at a time of 0 hours. 
 
 
Percent Area of Wound  
 
The percent area that the cells took up on the well over time  was measured using a data 
analysis program written in ImageJ.  This program analyzed the amount of free space on each 
image as it was imported into ImageJ and listed results as the amount of cells covering the plate 
in each image.  The code developed to do this analysis and steps taken to collect the percent area 
can be found in Appendix C.  This data was analyzed by first calculating the amount of space on 
each well that was not covered by cells because that was the area of the wound that needed to 
still heal and subtracting this value from 100 percent in order to compare the area still needed to 
heal to the scratch width results.  A table summarizing the percent area results can be seen in 
Appendix B. 
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Wound Closure Rate: By Scratch Width and By Area  
 
 The wound closure rate was determined by graphing all averaged data points for scratch 
width (described in the Scratch Width Scratch Assay Results section) and percent area (described 
in the Percent Area section) over time.  Then a linear trendline was applied to the points and the 
wound closure rate was found by the equation:  
𝑊𝑜𝑢𝑛𝑑  𝐶𝑙𝑜𝑠𝑢𝑟𝑒  𝑅𝑎𝑡𝑒 = (𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝑊𝑖𝑑𝑡ℎ − (𝑦 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡))𝑇𝑖𝑚𝑒  
The wound closure rate was found for all replicates for synthetic and recombinant cCBD-LL37, 
fCBD-LL37, and WT conditioned media, and then averaged together.  Error was found using the 
standard error discussed below.  A table summarizing the wound closure rate results is in 
Appendix B. 
 
Error 
 
 Each scratch itself and image taken was unique, since the scratches were made by hand 
with a pipet tip and images were not done in exactly the same location on the plate at each time 
point; thus, error was relatively high.  For all values, the standard error was used to analyze the 
data, calculated using the equation:  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝐸𝑟𝑟𝑜𝑟 = 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛𝑛!/!  
where n is the number of trials. 
 
Normalization 
 
 Due to the original scratch width not being the same for every test the data was 
normalized in order to allow comparison of the results over time.  The data was normalized so 
that the first point, at a time of 0 hours, was considered to be 100 percent, or the point with the 
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widest scratch.  Each set of data was normalized to the original scratch width.  To do this the 
average scratch width at each time point, including the first time point at 0 hours, was divided by 
the first average scratch width at 0 hours. 
Propagated error was found when normalizing the data, since both of the numbers 
being divided had error.  For the scratch width and percent area error the propagated error was 
calculated using the equation:  
𝑃𝑟𝑜𝑝𝑎𝑔𝑎𝑡𝑒𝑑  𝐸𝑟𝑟𝑜𝑟 = 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 ∗ 𝑆𝑡.𝐷𝑒𝑣.𝐴𝑣𝑔 ! + 𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙  𝑆𝑡.𝐷𝑒𝑣.𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙  𝐴𝑣𝑔 ! 
where the “original” data used is the data to which the trial was normalized.  
 
Statistical Significance   
 
In order to determine if the data collected and results found were significant, a one-way 
analysis of variance (ANOVA) statistical test was used.  The number of replicates for each 
condition is listed in Figure 12.   
Sample Replicates (n) 
Control 25 
0.05-µM cCBD -LL37 5 
3-µM cCBD -LL37 4 
12-µM cCBD -LL37 5 
0.05-µM LL37 4 
3-µM LL37 4 
12-µM LL37 4 
cCBD-LL37 CM 4 
fCBD-LL37 CM 4 
WT CM 4 
Figure 12: Number of replicates analyzed for the scratch width, percent area, and wound closure 
rate.  All samples were n > 4 with 25 control replicates. 
 
In instances where statistical significance was found (p<0.050), a post-hoc Tukey Test 
was used to locate the significance within the data set. One-way ANOVA on ranks tests were 
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performed on data sets where the equal variance condition could not be satisfied. All statistics 
were performed with SigmaPlot 12.5 software (Systat Software Inc., San Jose, CA). 
 
Rationalizing Concentration Choice 
 
The concentrations of synthetic, (+)AMP samples for LL37 and cCBD-LL37 were 
chosen to be 0.05-µM, 3-µM, and 12-µM based on literature and our own biocompatibility 
investigations. We also performed preliminary MTT assays with our synthetic AMPs shown in 
Figure 13, which measure the ability of healthy fibroblasts to reduce MTT into formazan using 
visible spectroscopy. In short, CT 1005 fibroblasts were seeded on well plates at 4,000 cells/well 
and exposed to serial dilutions of AMPs between 0.01-µM and 50-µM. The resulting profile is 
similar to what has been reported in literature (Figure 8), demonstrating a wound healing effect 
between 0.5-µM and 3-µM, no effect on the rate of healing below 0.05-µM, and toxicity above 
10-µM. Thus, we chose values within these three regimes. 
 
Figure 13: MTT Assay with CT Fibroblasts and both LL37 and cCBD-LL37.  The error bars 
represent the standard deviation.  All data was normalized to a no – AMP control as shown by 
the dotted line on the graph.  Anything greater than this line was considered relatively “more 
proliferative” and anything below the line was relatively “less proliferative.” The AMP 
concentrations of 0.05-µM, 3-µM, and 12-µM used for the experiments are also shown.  
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Results 
 
 Controls 
 
For each scratch assay that was done a minimum of one control well with no AMP was 
also scratched.  A representative panel of images demonstrating control well gap closure over 
time is presented in Figure 14.  A total of n > 24 replicates were collected for the scratch width 
controls and percent area control that were averaged together and normalized.  The normalized 
average of each control over time is plotted in Figure 15.  The individual normalized scratch 
width, normalized percent area, and error calculations for each data set are summarized in 
Appendix B. 
 
 
 
Figure 14: Control scratch images with no AMP at time points of 0 hours, 10 hours, and 22 
hours during the scratch closure. Additional time points at 4 and 15 hours (not shown) were also 
taken for each experiment. 
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Figure 15: Overall normalized scratch width control versus overall normalized area to be closed 
over the time period of scratch closure.  The error bars were found by calculating the propagated 
error at each time point.  There was no statistical significance observed between the controls 
using one-way ANOVA, p<0.05. 
 
 
(+) Synthetic LL37 and cCBD-LL37 AMP Scratch Assay Results  
 
Synthetic LL37 and cCBD-LL37 AMP were used at concentrations of 0.05-µM, 3-µM, 
and 12-µM.  A representative example of a scratch closing at different concentrations of cCBD-
LL37 and LL37 over time is shown in Figure 16 and Figure 17, respectively.  
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cCBD-LL37 AMP  
 
 
 
Figure 16: Three synthetic cCBD-LL37 AMP scratch images at concentrations of 0.05-µM, 3-
µM, and 12-µM at time points of 0 hours, 10 hours, and 22 hours during the scratch closure. 
Additional time points at 4 and 15 hours (not shown) were taken for each experiment.  
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LL37 AMP 
 
 
 
Figure 17: Three synthetic LL37 AMP scratch images at concentrations of 0.05-µM, 3-µM, and 
12-µM at time points of 0 hours, 10 hours, and 22 hours during the scratch closure. Additional 
time points at 4 and 15 hours (not shown) were taken for each experiment.  
 
The scratch width versus time for each AMP compared to the control is shown for 0.05-
µM, 3-µM, and 12-µM concentrations in Figure 18, 19 and 20, respectively. Similarly, the 
exposed area percentage over time is demonstrated for each AMP at 0.05-µM, 3-µM, and 12-µM 
in Figure 21, 22, and 23, respectively.  A minimum of n = 4 replicates were collected for each 
test and some had n = 5 replicates (Figure 12).  All the trials collected and graphed were 
averaged together and normalized.  The individual normalized scratch width, normalized percent 
area, and error calculations for each concentration are summarized in Appendix B. 
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Figure 18: Overall normalized scratch width of 0.05-µM AMP cCBD-LL37 and LL37 plotted 
against the overall average control measurements with no added peptide over the time period of 
scratch closure.  The error bars were found by calculating the propagated error at each time 
point.  There was no statistical significance (p<0.05) seen for any time point. 
 
 
Figure 19: Overall normalized scratch width of 3-µM AMP cCBD-LL37 and LL37 plotted 
against the overall average control measurements with no added peptide over the time period of 
scratch closure.  The error bars were found by calculating the propagated error at each time 
point. (*) Indicates p < 0.05 at time points for cCBD-LL37 vs. other samples. 
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Figure 20: Overall normalized scratch width of 12-µM AMP cCBD-LL37 and LL37 plotted 
against the overall average control measurements with no added peptide over the time period of 
scratch closure.  The error bars were found by calculating the propagated error at each time 
point. (*) Indicates p < 0.05 at time points for cCBD-LL37 vs. other samples. 
 
 
Figure 21: Overall normalized area still needed to be closed of 0.05-µM AMP cCBD-LL37 and 
LL37 plotted against the overall average control measurements with no added peptide over the 
time period of closure.  The error bars were found by calculating the propagated error at each 
time point. (*) Indicates p < 0.05 at time points for cCBD-LL37 vs. other samples. 
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Figure 22: Overall normalized area still needed to be closed of 3-µM AMP cCBD -LL37 and 
LL37 plotted against the overall average control measurements with no added peptide over the 
time period of closure.  The error bars were found by calculating the propagated error at each 
time point.  There was no statistical significance (p<0.05) seen between any time points.  
 
 
Figure 23: Overall normalized area still needed to be closed of 12-µM AMP cCBD-LL37 and 
LL37 plotted against the overall average control measurements with no added peptide over the 
time period of closure.  The error bars were found by calculating the propagated error at each 
time point. (*) Indicates p < 0.05 at time points for cCBD-LL37 vs. other samples. 
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Recombinant cCBD-LL37 & fCBD-LL37 and WT CM Scratch Assay Results 
 
Similar to scratch assays with synthetic AMPs, a representative example of a scratch 
closing with cCBD-LL37, fCBD-LL37, and WT conditioned media is shown in Figure 24.  
Conditioned Media  
 
 
 
Figure 24: Different conditioned media used with CT 1005 cells during a scratch assay at time 
points of 0 hours, 10 hours, and 22 hours during the scratch closure.  Additional time points at 4 
and 15 hours (not shown) were taken for each experiment.  
 
The scratch width data collected for recombinant CBD-LL37. cCBD-LL37, fCBD-LL37, 
and WT CM is graphed in Figure 25 and the exposed area percentage over time is demonstrated 
in Figure 26.  A total of n = 4 replicates were conducted for each of the recombinant CBD-LL37. 
cCBD-LL37, fCBD-LL37, and WT CM media.  The individual normalized scratch width, 
normalized percent area, and error calculations for each data set are summarized in Appendix B. 
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Figure 25: Recombinant cCBD-LL37 and fCBD-LL37 and WT CM normalized scratch width 
plotted against the overall average control measurements with no added conditioned media over 
the time period of scratch closure.  The error bars were found by calculating the propagated error 
at each time point. There was no statistical significance (p<0.05) seen between any data set.  
 
 
 
Figure 26: Overall normalized area still needed to be closed of recombinant cCBD -LL37 and 
fCBD-LL37 and WT CM plotted against the overall average control measurements with no 
added peptide over the time period of closure.  The error bars were found by calculating the 
propagated error at each time point. (*) Indicates p < 0.05 at time points for cCBD-LL37 CM vs. 
other samples. 
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Wound Closure Rate  
 
The wound closure rates determined for each sample analyzed using scratch width and 
analyzed using percent area are graphed below in Figures 27 and 28, respectively.  All individual 
wound closure rates calculated and the error associated with each sample are summarized in 
Appendix B.  
 
Figure 27a: Wound closure rate of the averaged scratch width over the 22-hour time period.  
The error bars were found by calculating the standard error of each test. Statistical analyses were 
performed using one-way ANOVA with p<0.05. Statistical significance was observed and is 
described in Figure 26b, Figure 26c, and Figure 26d.   
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Figure 27b: Wound closure rate of the average scratch width of synthetic cCBD-LL37 vs. no 
AMP control over the 22-hour time period.  (*) Indicates p < 0.05 for samples vs.12-µM cCBD -
LL37.   
 
 
Figure 27c: Wound closure rate of the average scratch width of synthetic cCBD -LL37 vs. no 
AMP control over the 22-hour time period.  (*) Indicates p < 0.05 for samples vs.12-µM LL37.   
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Figure 27d: Wound closure rate of the average scratch width of synthetic cCBD -LL37 vs. no 
AMP control over the 22-hour time period.  The 3 conditioned media samples were not 
statistically significant compared to each other but were statistically significant compared to the 
no AMP control.  (*) Indicates p < 0.05 for samples vs. 3-µM cCBD -LL37.  (**) Indicates p < 
0.05 for samples vs. 12-µM cCBD -LL37.  
 
  
Figure 28a: Wound closure rate of the average percent area over the 22-hour time period.  The 
error bars were found by calculating the standard error of each test. Statistical analyses were 
performed using one-way ANOVA with p<0.05. Statistical significance was observed and is 
described in Fig. 27(b-d). 
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Figure 28b: Wound closure rate of the average percent area of synthetic cCBD -LL37 vs. no 
AMP control over the 22-hour time period.  (*) Indicates p < 0.05 for samples vs. cCBD-LL37 
CM.  (**) Indicates p < 0.05 for samples vs. fCBD-LL37 CM.  (***) Indicates p < 0.05 for 
samples vs. WT CM.   
 
 
Figure 28c: Wound closure rate of the average percent area of synthetic LL37 vs. no AMP 
control over the 22-hour time period.  (*) Indicates p < 0.05 for samples vs. cCBD-LL37 CM.  
(**) Indicates p < 0.05 for samples vs. fCBD-LL37 CM.  (***) Indicates p < 0.05 for samples vs. 
WT CM.  (****) Indicates p < 0.05 for samples vs. 12 µM cCBD -LL37. 
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Figure 28d: Wound closure rate of the average percent area of conditioned media vs. no AMP 
control over the 22-hour time period.  The 3 conditioned medias wound closure rates were not 
statistically significant from each other but all were statistically significant (p < 0.05) compared 
to the no AMP control.   
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Discussion 
 
Controls 
  
 The average scratch width control over time and the percent area over time controls are 
not exactly the same as shown in Figure 15.  Although these controls are not statistically 
significant different from one other, the area control appears to be slower in most cases.  For 
both analyses the same images over time were used and the results were averaged together.  The 
different result comes from the different methods of data analysis.  For the scratch width analysis 
only 10 lines are drawn to measure the width while most studies that use this method draw 
approximately 100 lines per image.  Although the 10 lines is a good representation of the scratch 
width, it is only an average of the precise scratch width.  Most studies that use this method draw 
approximately 100 lines.  The percent area was found using a computer program and the amount 
of area was calculated.  There was no way to determine if each well had the exact same 
confluency, if any debris on the well affected the collected results, or if the program had 
inaccuracies due to the contract seen in each individual image.   
 
(+) Synthetic LL37 and cCBD-LL37 AMP Results 
 
 In general, it was observed that LL37 healed at a faster rate than cCBD -LL37 and any 
concentration of AMP used also healed at a slower rate than control.  From the scratch width 
results in Figure 18, Figure 19, and Figure 20, at all concentrations the scratch width of cCBD -
LL37 is larger than LL37 at each time point.  Also from this data it was seen that both AMPs, no 
matter what concentration, healed at a slower rate than the no AMP control.  For the percent area 
results in Figure 21, Figure 22, and Figure 23, there is a similar result that showed that cCBD -
LL37 had more area to heal on the well at each time point than LL37 and both had more area to 
heal over time when compared to the no AMP control.  This is one reason why the wound 
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closure rate analysis provided an alternative way to evaluate the data and validate scratch width 
and area findings. 
 The no AMP control healed at a faster rate than any concentration of cCBD-LL37 or 
LL37.  This could be because the scratch assay was carried out in vitro.  Proliferation and 
migration of keratinocytes are the most important aspects in wound healing and growth factors 
and cytokines have a significant influence upon these processes (Carretero et al., 2008).  LL37 
helps to promote wound healing by inducing chemotaxis of immune cells as well as dendritic 
cell differentiation and also induces the expression of chemokines and cytokines that help to heal 
wounds by activating (Carretero et al., 2008).  Also, after the migration and proliferation of 
keratinocytes at the wound edge has started, proliferation of dermal fibroblasts in the area of the 
wound follows.  The fibroblasts deposit large amounts of extracellular matrix and also help the 
wound contract to heal (Werner & Grose, 2003).  One study looked into the different signals that 
are activated in order to help a wound heal.  The expression of PDGF in the dermis and 
granulation tissue helped to heal a wound and studies done with diabetic mice had less PDGF 
that indicated that a certain expression level of PDGFs and their receptors as an essential part of 
normal wound repair (Werner & Grose, 2003).  Since the study was conducted in vitro LL37 
would not have been able to signal PDGF or other wound healing activities but a study could be 
done looking into the different wound healing signals and whether their absence from in vitro 
studies would inhibit wound healing.  Without being able to signal the wound healing activities 
the addition of AMP may not speed up the wound healing process.  Another wound healing 
study done in vivo on mice with recombinant and synthetic P-LL37 with a N-terminus analyzed 
the re-epithelialization of the wound.  It was determined that the control wells keratinocyte layer 
was incomplete while the wounds treated with LL37 showed close to complete re-
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epithelialization.  This demonstrated that the healing process was accelerated when LL37 was 
used in vivo (Reinaldo et al., 2011).  In the future it would be interesting to do a similar study in 
vivo to see if the same results would be achieved as seen in the previously described study. 
The reasoning for observing slower migration in both the addition of AMPs in general vs. 
no AMPs and cCBD-LL37 vs. LL37 concentrations is likely similar.  These results may be 
because cCBD-LL37 and LL37 have different structures. This different structure has been the 
cause of slightly higher antimicrobial activity observed previously by our group by cCBD-LL37. 
Since mechanisms against bacteria and mammalian cell membranes are related, higher activity 
by cCBD-LL37 could cause it to be more destructive toward fibroblast membranes thus causing 
slower healing. Also, LL37 has lower antimicrobial activity than cCBD-LL37 that could inhibit 
its wound closure rate, but both wounds would heal at a slower rate than the control (Wang, 
Nagrarajan, & Camesano, 2014).   
 Another significant finding was that the 12-µM concentration of both cCBD -LL37 and 
LL37 inhibited cell mobility and wound closure as shown in Figure 27b and Figure 28b.  This is 
most likely because 12-µM has been shown to be toxic to cells (Duplantier & van Hoek, 2013).  
A toxic concentration to cells can cause necrosis in which cells lose membrane integrity and die 
rapidly as a result of cell lysis, the cells can stop growing and dividing, or they can die (Usmani, 
2011).  This inhibited wound healing is apparent when compared to the 0.05-µM and 3-µM 
concentrations.  Therefore, the 12-µM concentration would not be used in an ECM scaffold due 
to its toxicity.  In the future different tests could look into the molecular mechanisms behind 
LL37 versus bacterial membranes and mammalian membranes, the cell morphology changes 
with an increase in AMP concentration, or the mechanisms of cell death that could help explain 
the inhibited wound healing at the 12-µM concentration. 
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Recombinant cCBD-LL37 & fCBD-LL37 and WT CM Results 
 
 From the scratch width results (Figure 18, Figure 19, and Figure 20), percent area results 
(Figure 21, Figure 22, and Figure 23), and wound closure rate results (Figure 27d and Figure 
28d) it is evident that the cCBD-LL37 CM, fCBD-LL37 CM, and WT CM all healed at a faster 
rate than the no AMP control.  The results show that something in the CM was influencing the 
cells growth in the scratch assays.  Two possibilities of why they healed at a faster rate could 
have been due to something secreted by the cancer cells into the media or if the CT 1005 cells 
had been genotypically or phenotypically altered by the presence of H1299-conditioned medium.  
Further studies would need to be completed to determine the exact cause of these results.   
 Another notable observation was that there is no statistical significance seen between 
any of the different CM types.  This was different than what we originally hypothesized.  Since 
WT had no AMPs, we hypothesized that it would act like a control, no AMP well but there 
seemed to be something collected in this media that made it act like the cCBD-LL37 and fCBD-
LL37 CM.  This indicates that whatever is in the media is having a stronger effect on wound 
healing than the presence of AMPs and there could be very small concentrations of AMPs in the 
CM that are not affecting the wound closure rate. 
 In another study, it was found that the activity of mesenchymal stem cell (MSC) 
conditioned media played a role in skin wound closure by affecting both dermal fibroblast and 
keratinocyte migration, along with a contribution to the formation of extracellular matrix.  It was 
also found that the enhanced wound closure rate was due to accelerated cell migration and not 
due to increased cell proliferation (Walter, Wright, Fuller, MacNeil, & Johnson, 2012).  
Although the conditioned media was taken from stem cells rather than cancer cells it could be 
possible they would act the same.  Some future studies to look into would be to look into 
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whether the cells are proliferating and closing the gap or if they are actually closing the gap due 
to cell migration, determine the actual concentration of AMP within the conditioned media when 
1-mL is used for a scratch assay, or the differences between the conditioned medias used and 
why they showed similar wound healing.  
 
Wound Closure Rate 
 
 The wound closure rate was helpful to use in verifying the results seen with the scratch 
width and percent area analyses.  Similar trends were observed for the wound closure rate 
graphs.  This method would allow for the comparison of several different cell types, AMP types, 
and concentrations.  The bar graph presentation of the wound closure rate also makes it easy to 
compare many data sets quickly.  Finally, this method would allow for hundreds of data sets to 
be compiled and compared easily with any future scratch assays.  
 
Sources of Error 
 
The experiment had several areas where error could be introduced, but many replicates of 
each test were done to try and mitigate this error and the standard error was also used.  In the 
experiment there was no way to make the starting scratch width the exact same for every test 
because they were scratched by hand so the data was normalized.  Other problems that were 
encountered with the scratch assay and culturing cells can be found in Appendix D.   
 
Overall Recommendations for ECM Incorporation of AMPs 
 
 One finding was that the results for any data analysis became more and more significant 
over time.  This is because over time, wound healing becomes more apparent.  
Before starting the scratch assays, we hypothesized that the addition of the cCBD moiety 
in the synthetic and recombinant cCBD-LL37 AMPs would not be significantly different than 
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unmodified LL37 at any of the concentrations.  This was true for both AMPs at the 0.05-µM and 
3-µM concentrations.  At the 12-µM concentration, there was a significant difference seen 
between the cCBD-LL37 and LL37 as well as the control.  Since this concentration is toxic to 
cells and clearly inhibited wound closure, this concentration would not be used in an ECM 
scaffold.  I also hypothesized that the highest migration rate of the CT 1005 cells would be 
observed at the middle concentration of 3-µM because that was determined to be in the wound 
healing range for LL37.  This was not shown by the results and overall when any concentration 
of AMP was added to the CT 1005 cells, would closure was inhibited.  This was most likely due 
to the fact that the scratch assay was carried out in vitro so it seems that many of the wound 
healing activities signaled by the AMP were not possible. 	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Conclusions 
 
In order to develop a broad-spectrum chronic wound collagen dressing based on AMPs, 
several obstacles have to be overcome.  One of the main drawbacks with almost all current 
antimicrobial treatments is the absence of broad-spectrum antimicrobial activity because over 
200 species of bacteria can reside in a single chronic wound.  Also, other obstacles with the use 
of AMPs for wound healing include toxicity, stability, and high manufacturing costs. We 
hypothesize that tethering AMPs onto collagen-based wound dressings will ultimately overcome 
these limitations by reducing toxicity (Onaizi, 2011), increasing AMP stability (Bagheri, 2009), 
and reducing costs by allowing a local therapeutic dosage of AMP to be delivered to a wound in 
the right concentration. 
In this study the goal was to conduct scratch assay migration tests with synthetic cCBD -
LL37, synthetic LL37, recombinant cCBD-LL37, recombinant fCBD-LL37, and WT CM, in 
solution and determine their ability to promote wound healing of CT 1005 fibroblasts in vitro 
over time at concentrations of 0.05-µM, 3-µM, and 12-µM.  Our original hypothesis was that the 
addition of the cCBD moiety in the synthetic and recombinant cCBD -LL37 AMPs would not be 
significantly different than unmodified LL37 at any of the concentrations.  Of the concentrations 
tested, this proved to be true for the 0.05-µM and 3-µM concentrations.  At the 12-µM 
concentration there was a significant difference seen between the cCBD-LL37 and LL37 but this 
concentration was also toxic to the cells and would not be used in the future for an ECM 
scaffold.  We also hypothesized that the highest migration of the fibroblasts would be observed 
at the middle concentration of 3-µM based on literature suggestions and preliminary 
experimental results. On the contrary, the results presented here showed that any concentration 
of AMP added to CT 1005 cells inhibited wound healing.  This was most likely due to the 
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scratch assay being carried out in vitro.   A final major finding was that the CM healed at a faster 
rate than the no AMP controls and there was no statistical significance between each individual 
CM type.  It is uncertain what exactly is making the wound heal faster with the addition of the 
CM but further tests studying cell proliferation versus cell migration, the composition of the 
conditioned media, and other tests would need to be conducted in order for this to be determined. 
The next step of this study would be to evaluate migration of fibroblasts when exposed to 
CBD-LL37 tethered onto collagen at a fixed concentration. It has been suggested that tethering 
reduces toxicity of AMPs, so this suggests that the levels of toxicity, particularly at 12-µM, 
would potentially reduce as a result of tethering and more migration might be seen.  Also, it 
would be interesting to do tests to determine exactly what was making the conditioned media 
heal at a faster rate than the control and why the WT CM acted the same as the cCBD-LL37 and 
fCBD-LL37.  Finally, in the future it might be worthwhile to do an in vivo scratch assay with 
AMPs to determine if there is a difference in the AMPs wound healing ability or do a chamber-
based assay to study cell migration in vitro. 
The long-term goal of this project is to tether AMPs to collagen-based chronic wound 
dressings using the CBDs in order to reduce AMP toxicity, improve AMP stability and 
strategically deliver a broadly-active antimicrobial agent to prevent chronic wound infection all 
while promoting healing.  The results from this scratch assay will help show the need for a new 
approach in delivery modified CBD-LL37 via tethering and follow-up in vivo studies for 
commercial considerations, as well as to identify appropriate AMP delivery concentrations to 
choose for use in an ECM scaffold in the hopes of developing a new wound healing treatment. 
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Appendices 
 
Appendix A: Background Figures 
 
 
Figure 5: Advantages and disadvantages of using topical antimicrobial therapies including 
creams and ointments (Lipsky & Christopher, 2009). 
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Figure 6: Several topical antimicrobial wound healing products and formulations currently 
available listed with advantages and disadvantages (Lipsky & Christopher, 2009). 
 
 
 
Figure 7: Several considerations and factors developed by clinicians and industry in order to 
develop the idea topical antimicrobial therapy (Lipsky & Christopher, 2009). 
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Appendix B: Scratch Width, Percent Area, and Wound Closure Rate Summarized 
Data 
Scratch Width Results 
Scratch Width All Controls (n = 25) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2691.4144 2330.8705 1634.8421 1110.8032 645.9402 
Normalized Average 1.0000 0.8660 0.6074 0.4127 0.2400 
Standard Deviation 389.7490 362.3611 419.7691 422.4498 280.8504 
Standard Error 14.2316 13.2316 15.3278 15.4257 10.2552 
Propagated Error 0.2048 0.1840 0.1791 0.1680 0.1100 
 
Scratch Width 0.05-µM cCBD (n = 5) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2681.7887 2340.1191 1635.7559 1141.3511 631.0478 
Normalized Average 1.0000 0.8726 0.6099 0.4256 0.2353 
Standard Deviation 294.6066 316.9612 385.2706 437.1497 284.6632 
Standard Error 24.0545 25.8798 31.4572 35.6931 23.2427 
Propagated Error 0.1554 0.1522 0.1585 0.1696 0.1092 
Scratch Width 0.05-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2459.6303 2072.3135 1482.6088 931.4415 595.8637 
Normalized Average 1.0000 0.8425 0.6028 0.3787 0.2423 
Standard Deviation 327.6107 332.4127 398.8904 406.7564 232.4626 
Standard Error 25.8999 26.2795 31.5351 32.1569 18.3778 
Propagated Error 0.1884 0.1757 0.1810 0.1729 0.0999 
 
Scratch Width 3-µM cCBD (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2831.3246 2506.1779 1998.0469 1486.9157 848.6870 
Normalized Average 1.0000 0.8852 0.7057 0.5252 0.2997 
Standard Deviation 321.4777 303.5605 439.5395 392.2482 359.2549 
Standard Error 29.3468 27.7112 40.1243 35.8072 32.7953 
Propagated Error 0.1606 0.1470 0.1747 0.1508 0.1314 
Scratch Width 3-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2679.0280 2418.3465 1910.6533 1284.2625 736.5164 
Normalized Average 1.0000 0.9027 0.7132 0.4794 0.2749 
Standard Deviation 261.8444 312.9655 371.6593 448.4365 289.7919 
Standard Error 23.9030 28.5697 33.9277 40.9365 26.4543 
Propagated Error 0.1382 0.1464 0.1553 0.1738 0.1115 
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Scratch Width 12-µM cCBD (n = 5) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2483.1817 2334.7475 2065.6024 1803.2282 1490.1621 
Normalized Average 1.0000 0.9402 0.8318 0.7262 0.6001 
Standard Deviation 363.3890 348.3336 398.3944 456.5854 484.4088 
Standard Error 29.6706 28.4413 32.5288 37.2800 39.5518 
Propagated Error 0.2070 0.1965 0.2014 0.2124 0.2139 
Scratch Width 12-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2560.3286 2300.9731 1916.4780 1504.3373 1085.9351 
Normalized Average 1.0000 0.8987 0.7485 0.5876 0.4241 
Standard Deviation 454.8731 419.2356 501.3643 515.4977 430.1755 
Standard Error 41.5240 38.2708 45.7681 47.0583 39.2695 
Propagated Error 0.2513 0.2287 0.2367 0.2268 0.1841 
 
Scratch Width cCBD CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2806.0110 2422.6658 1568.4900 954.9729 448.5060 
Normalized Average 1.0000 0.8634 0.5590 0.3403 0.1598 
Standard Deviation 269.6917 275.3082 327.8817 302.6230 196.6342 
Standard Error 24.6194 25.1321 29.9314 27.6256 17.9502 
Propagated Error 0.1359 0.1285 0.1286 0.1127 0.0717 
Scratch Width fCBD CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2891.9010 2483.6071 1640.3616 1019.3522 482.4578 
Normalized Average 1.0000 0.8588 0.5672 0.3525 0.1668 
Standard Deviation 272.1240 318.4470 377.2553 373.2399 209.5497 
Standard Error 24.8414 29.0701 34.4385 34.0720 19.1292 
Propagated Error 0.1331 0.1366 0.1409 0.1333 0.0741 
Scratch Width WT CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 2609.2594 2212.1437 1499.4947 982.2413 414.8622 
Normalized Average 1.0000 0.8478 0.5747 0.3764 0.1590 
Standard Deviation 837.4636 749.9494 552.6582 401.6456 226.1670 
Standard Error 76.4496 68.4607 50.4506 36.6651 20.6461 
Propagated Error 0.4539 0.3958 0.2809 0.1957 0.1006 
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Percent Area Results 
Percent Area All Controls (n = 25) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 46.9158 37.7140 32.9095 24.8215 19.2277 
Normalized Average 1.0000 0.8039 0.7015 0.5291 0.4098 
Standard Deviation 6.1737 4.7583 6.7802 8.5085 7.9625 
Standard Error 0.7276 0.5608 0.7991 1.0027 0.9384 
Propagated Error 0.1861 0.1465 0.1715 0.1943 0.1781 
 
Percent Area 0.05-µM cCBD (n = 5) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 47.1950 40.8773 35.3149 32.2567 21.3162 
Normalized Average 1.0000 0.8661 0.7483 0.6835 0.4517 
Standard Deviation 4.8051 6.1712 7.5306 11.0436 10.7867 
Standard Error 1.2407 1.5934 1.9444 2.8514 2.7851 
Propagated Error 0.1440 0.1577 0.1768 0.2441 0.2331 
Percent Area 0.05-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 42.6329 36.1496 27.4107 22.0085 18.6949 
Normalized Average 1.0000 0.8479 0.6429 0.5162 0.4385 
Standard Deviation 6.0188 8.1085 10.4940 9.7907 7.2446 
Standard Error 1.5540 2.0936 2.7095 2.5280 1.8705 
Propagated Error 0.1997 0.2247 0.2624 0.2409 0.1809 
 
 
Percent Area 3-µM cCBD (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 44.9917 33.4828 30.9117 25.3984 17.3332 
Normalized Average 1.0000 0.7442 0.6871 0.5645 0.3853 
Standard Deviation 2.9934 10.8875 6.6865 8.2801 8.5237 
Standard Error 0.8641 3.1430 1.9302 2.3903 2.4606 
Propagated Error 0.0941 0.2470 0.1555 0.1878 0.1912 
Percent Area 3-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 47.8284 37.1988 29.5213 25.4964 13.6398 
Normalized Average 1.0000 0.7778 0.6172 0.5331 0.2852 
Standard Deviation 6.3253 5.4871 5.3917 3.2882 8.7107 
Standard Error 1.8260 1.5840 1.5565 0.9492 2.5146 
Propagated Error 0.1870 0.1541 0.1392 0.0985 0.1860 
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Percent Area 12-µM cCBD (n = 5) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 34.8532 33.5529 30.5033 27.7889 25.4281 
Normalized Average 1.0000 0.9627 0.8752 0.7973 0.7296 
Standard Deviation 4.6494 3.4241 5.9890 5.2541 8.1835 
Standard Error 1.2005 0.8841 1.5463 1.3566 2.1130 
Propagated Error 0.1887 0.1617 0.2077 0.1845 0.2542 
Percent Area 12-µM LL37 (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 34.5131 29.9307 25.6691 18.5429 14.0211 
Normalized Average 1.0000 0.8672 0.7437 0.5373 0.4063 
Standard Deviation 11.2706 11.6372 9.6207 10.7029 15.2807 
Standard Error 2.9101 3.0047 2.4841 2.7635 3.9455 
Propagated Error 0.4618 0.4403 0.3697 0.3563 0.4622 
 
Percent Area cCBD CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 47.5274 37.5277 22.7795 13.6673 4.0906 
Normalized Average 1.0000 0.7896 0.4793 0.2876 0.0861 
Standard Deviation 6.3708 5.0419 4.8423 5.4570 2.5720 
Standard Error 1.8391 1.4555 1.3979 1.5753 0.7425 
Propagated Error 0.1896 0.1499 0.1204 0.1211 0.0553 
Percent Area fCBD CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 44.7483 33.7918 25.7919 13.9301 4.2347 
Normalized Average 1.0000 0.7552 0.5764 0.3113 0.0946 
Standard Deviation 7.1402 7.9139 7.1538 10.8148 3.4502 
Standard Error 2.0612 2.2845 2.0651 3.1220 0.9960 
Propagated Error 0.2257 0.2140 0.1844 0.2467 0.0786 
Percent Area WT CM (n = 4) 
Time Point 0 Hours 4 Hours 10 Hours 15 Hours 22 Hours 
Average (µm) 41.8989 32.2766 23.4461 12.2856 4.2865 
Normalized Average 1.0000 0.7703 0.5596 0.2932 0.1023 
Standard Deviation 3.0389 5.4683 5.6792 6.4241 2.5946 
Standard Error 0.8773 1.5786 1.6394 1.8545 0.7490 
Propagated Error 0.1026 0.1420 0.1415 0.1548 0.0624 
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Wound Closure Rate Results 
 
Scratch Width Wound Closure Rate  Standard Error 
12-µM cCBD  0.0183 0.0017 
12-µM LL37  0.0268 0.0011 
3-µM cCBD 0.0321 0.0007 
3-µM LL37 0.0342 0.0016 
0.05-µM cCBD 0.0359 0.0026 
0.05-µM LL37 0.0358 0.0009 
cCBD CM 0.0398 0.0006 
fCBD CM 0.0393 0.0008 
WT CM 0.0391 0.0006 
Control 0.0359 0.0004 
 
Percent Area Wound Closure Rate Standard Error 
12-µM cCBD  0.0148 0.0038 
12-µM LL37  0.0299 0.0054 
3-µM cCBD 0.0253 0.0012 
3-µM LL37 0.0306 0.0027 
0.05-µM cCBD 0.0236 0.0040 
0.05-µM LL37 0.0262 0.0027 
cCBD CM 0.0421 0.0013 
fCBD CM 0.0412 0.0016 
WT CM 0.0410 0.0013 
Control 0.0264 0.0012 
 
 
Appendix C: ImageJ Program*  
 
run("Images to Stack", "name=Stack title=[] use"); 
run("Find Edges", "stack"); 
run("Find Edges", "stack"); 
setAutoThreshold("Default dark"); 
//run("Threshold..."); 
setOption("BlackBackground", false); 
run("Make Binary", "method=Default background=Default calculate black"); 
run("Fill Holes", "stack"); 
run("Analyze Particles...", "size=0-100000000 show=Outlines summarize stack" 
 
The process to analyze a set of images and determine the percent area required many 
steps; (1) Stack the images to allow for bulk analysis (Image>stack>images to stack), (2) The 
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borders of the cells were found and this was done twice to create a better outline (Process>find 
edges), (3) The threshold function was used to reduce the impact of smudging and streaking in 
the analysis (Image>adjust>threshold>0/16>dark background>apply) 
 
(4) The image was made binary to fill the holes in order to create an outline of the wound 
(Process>binary>make binary and Process>binary>fill holes), (5) A table of data for all the 
images was outputted which included percent area covered by cells (Analyze>analyze 
particles>size 0-infinity circularity 0-1>show outlines>summarize.   
 
 
*Development of this program was completed with the help of Nick Bergstrom (WPI)  
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Appendix D: Troubleshooting Guide 
 
Culturing cells can be difficult and requires some trial and error.  The following table shows 
some problems that could be encountered during this experiment and how to resolve these 
problems.  Images are provided to show some examples.  
 
Problem Resolution, Discussion and Example Images 
Scratches 
are 
inconsistent 
Scratch at an angle (a) is 
more inconsistent 
Scratch with the pipet 
straight up and down 
(b)(90 degree normal to 
surface) is more 
consistent. 
No peptide added to this image of a scratch taken at 
an approximate 45-degree angle like holding a 
pencil with a 5x objective lens and a 10x eyepiece 
on microscope. 
 
No peptide added to this image of a scratch taken at 
a 90-degree angle with a 5x objective lens and 10x 
eyepiece on microscope. 
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Difficulty 
seeding a 
consistent 
confluent 
monolayer 
I seeded approximately 
135,000 cells per well on 
a 6-well plate and let 
them grow for 24-48 
hours before scratching 
the surface.  
No peptide added to this confluency image taken 
after approximately 24 hours after plating. 
 
No peptide added to this confluency image after 48 
hours from plating and before scratching. 
 
“Bad 
Scratches” 
made 
A good scratch generally 
fits into the field of view 
for a 10x objective lens 
on the microscope you 
are using.  The scratch 
has a consistent width 
throughout and is pretty 
straight across the well.  
A bad scratch would be 
either too big or very 
small.  Also, a bad 
scratch would be wavy 
making it difficult to 
determine where the edge 
of the scratch is located.   
Concentration of 12-µM LL37 image of a “good” 
scratch taken at 0 hours  
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Concentration of 12-µM LL37 image of a “bad” 
scratch taken at 0 hours
 
Time interval 
for collecting 
images 
The scratches take 
around 24 hours to close 
so I took 5 different time 
points. Ideally more time 
points should be taken to 
see the scratch closing 
over time.   
 
Location 
along scratch 
to take image 
The entire length of the 
scratch does not fit onto 
the field of vision.  When 
you are still trying to get 
consistent scratches I 
would take multiple 
pictures of each scratch 
and take one 
measurement per picture 
using ImageJ.  When 
these measurements are 
similar it means your 
scratch is consistent and 
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I would then take three 
pictures per scratch and 
measure the scratch 
width in multiple 
locations (10) on each 
image using ImageJ. 
Note that it is important 
to never use an image 
near the edge of the 
scratch because the edge 
will always heal faster 
than the middle and 
could affect your scratch 
width over time.   
Time period 
for a scratch 
to close 
completely 
I found that a scratch 
with no AMP takes 
approximately 24 to 30 
hours to close completely 
depending on the width of 
the scratch at the start.  If 
the scratch is taking a 
much longer time to close 
then you scratched the 
surface of the tissue 
treated plate.  This 
occurs when you press 
too harshly on the cells in 
order to scratch them.  
Scratching the tissue 
treated wells affects cell 
migration rates which is 
why it takes so long to 
heal the scratch.  Usually 
you can see when you 
have pressed to hard on 
the surface because 
streaks and lines appear 
in the scratched area.  
Sometimes these streaks 
appear when the tissue 
treated surface has not 
been scratched but it is 
important to minimize the 
streaks. 
Example of a scratched tissue treated well with no 
added peptide using a 5x objective lens and 10x 
eyepiece. 
 
Cells are 
clumping on 
one area of 
the plate 
This usually happens 
when you swirl the plate 
in a circular motion.  
Cells act like sand and 
will congregate because 
of this.  Try instead 
shaking the plate back 
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and forth and side to side 
in order to evenly 
disperse the cells prior to 
incubating.   
Adding 
peptide 
 
With my experiments I 
added the peptide after 
scratching, rinsing, and 
adding media.  This 
allows you to keep the 
peptide on the plate and 
not disturb the cells as 
much.  Adding the 
peptide after also allows 
you to have to use less 
because you won’t need 
to add more when you 
rinse the cells.  A picture 
should be taken for time 
point zero immediately 
after peptide is added. 
 
Out-of-focus 
cells in my 
microscope 
images 
 
Rinse the cells once and 
then add media after 
scratching and before 
imaging.  This will get rid 
of any cells that are 
floating in the scratch to 
make a better image.   
Image of a scratch with no peptide added that was 
not thoroughly rinsed.
 
 
 
 
 
